Back to top
more

XOMA (XOMA)

(Delayed Data from NSDQ)

$25.20 USD

25.20
9,885

-0.70 (-2.70%)

Updated May 22, 2024 04:00 PM ET

After-Market: $25.49 +0.29 (1.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XOMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

XOMA Corporation [XOMA]

Reports for Purchase

Showing records 241 - 260 ( 328 total )

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 241

08/02/2013

Industry Report

Pages: 44

August And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 242

07/22/2013

Daily Note

Pages: 6

Phase 2 EOA Study Completes Enrollment and Top-Line Results Expected in October

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 243

07/03/2013

Company Report

Pages: 8

Divesture of Perindopril Franchise Allows Xoma to Maintain Equity Interest While Focusing on Gevokizumab

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 244

07/03/2013

Daily Note

Pages: 42

July And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 245

06/26/2013

Daily Note

Pages: 6

Servier''s Additional Investment in Polymyositis/Dermatomyostis Expands The Market Potential For Gevokizumab

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 246

06/24/2013

Industry Report

Pages: 16

American Diabetes Association 73rd Scientific Sessions (ADA June 21-25, 2013 Chicago)

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 247

06/20/2013

Daily Note

Pages: 6

Recent Weakness In Front Of Potential Catalysts Is A Buying Opportunity, In Our View:

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 248

06/16/2013

Daily Note

Pages: 6

ADA Preview: Gevokizumab''s Anti-Inflammatory Properties In T2D And Initial Preclinical Results for XmetD; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 249

06/13/2013

Company Report

Pages: 8

Gevokizumab Pilot Trial For Ultra-Rare Neutrophilic Dermatoses Subtype Could Be First To Market: Reiterate OUTPERFORM & Increasing FV to $6 For Time.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 250

06/03/2013

Daily Note

Pages: 29

June And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 251

05/10/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 252

05/10/2013

Company Report

Pages: 20

1Q13 - Progress with Gevokizumab

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 253

05/08/2013

Company Report

Pages: 11

Q1 Financials Included Pipeline Progress Updates; With Cash Runway Through 2014 and Multiple Material Catalysts, We Reiterate Our OUTPERFORM And $5 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 254

05/03/2013

Industry Report

Pages: 30

Emerging Pharmaceuticals-May and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 255

04/04/2013

Daily Note

Pages: 2

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 256

04/04/2013

Company Report

Pages: 23

A Deeper Dive into

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 257

04/01/2013

Industry Report

Pages: 30

Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 258

03/18/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 259

03/15/2013

Company Report

Pages: 10

We assume coverage with a $5 price target and a Buy rating,

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 260

03/12/2013

Company Report

Pages: 11

2012 Financials Beat Due To Expense Control;

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party